G1 Therapeuticslogo.JPG
G1 Therapeutics Announces Completion of Enrollment in Global Multi-Center Phase 3 Clinical Trial of Trilaciclib in Patients with Metastatic Colorectal Cancer
June 13, 2022 07:00 ET | G1 Therapeutics
RESEARCH TRIANGLE PARK, N.C., June 13, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that the last patient has been randomized...
researchdrivelogo.jpg
Global Cancer Stem Cells Market Estimated to Surpass $1,722.7 Million by 2026, and Grow at a CAGR of 10.3% during the Forecast Period [180-Pages] | Confirmed by Research Dive
April 20, 2022 09:00 ET | Research Dive
New York, USA, April 20, 2022 (GLOBE NEWSWIRE) -- Research Dive states that the global cancer stem cells market is estimated to garner a revenue of $1,722.7 million by 2026, and rise at a CAGR of...
researchdrivelogo.jpg
Global Cancer Stem Cells Market to Surpass $1,898.3 Million, Growing with a CAGR of 11.8% from 2019 to 2026, Post-COVID-19 Disaster by Research Dive
August 17, 2021 09:02 ET | Research Dive
New York, USA, Aug. 17, 2021 (GLOBE NEWSWIRE) -- A newest report on the global cancer stem cells market has been added by Research Dive to its repository. The report presents exhaustive insights on...
researchdrivelogo.jpg
Global Cancer Stem Cells Market to Witness Exponential Growth Owing to the Rising Efficiency of Stem Cell Therapy – Informative Report [180 Pages] by Research Dive
August 02, 2021 09:00 ET | Research Dive
New York, USA, Aug. 02, 2021 (GLOBE NEWSWIRE) -- A recently published report by Research Dive states that the global cancer stem cells market is expected to witness a rise in revenue from $786.3...
logo.jpg
Immunoscore® is now available in Rectal Cancer for expert clinical centers through an Innovation Access Program
May 11, 2021 08:00 ET | HalioDx
Immunoscore® heads up to become the standard precision tool for the “Watch and Wait” strategy in locally advanced rectal cancerExpert clinical centers already involved worldwide in this new Innovation...
logo.jpg
Paltown Development Foundation and HalioDx Team Up for Colorectal Cancer Testing Center
October 09, 2020 08:00 ET | HalioDx
Paltown Development Foundation and HalioDx Team Up for Colorectal Cancer Testing Center COLONTOWN University Launches Secure Platform for Colorectal Cancer Patients Marseille, France, October 9,...
DRGT_Logo_[RGB][1].jpg
DRGT Announces Hungarian Regulatory Authority Approval and Subsequent Initiation of a Phase 2 Trial of DRGT-119 in Patients With Chronic Anal Fissure
July 15, 2019 09:00 ET | Druggability Technologies Holdings Ltd
BUDAPEST, Hungary, July 15, 2019 (GLOBE NEWSWIRE) -- Druggability Technologies Holdings (DRGT) today announced the start of a phase 2 randomized, double-blind, placebo-controlled trial to evaluate...
Cohera Medical Inc.® Awarded Patent on its Biodegradable Sealant Technology
April 25, 2018 07:00 ET | Cohera Medical, Inc.
RALEIGH, N.C., April 25, 2018 (GLOBE NEWSWIRE) -- Cohera Medical, Inc., a leading innovator and developer of absorbable surgical adhesives and sealants, today announced that the U.S. Patent and...
ASLAN Pharmaceuticals Appoints Stephen Doyle as Head of China
January 18, 2018 01:00 ET | ASLAN Pharmaceuticals
SINGAPORE , Jan. 18, 2018 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (ASLAN, 6497.TT), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and orphan...
ASLAN Pharmaceuticals Announces Shortened Timeline to Commercialisation for Varlitinib in China
January 08, 2018 01:00 ET | ASLAN Pharmaceuticals
SINGAPORE, Jan. 08, 2018 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (ASLAN, 6497.TT), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and orphan...